Islet cell manufacturing compositions and methods of use
US-11945795-B2 · Apr 2, 2024 · US
US2020246760A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2020246760-A1 |
| Application number | US-202016805075-A |
| Country | US |
| Kind code | A1 |
| Filing date | Feb 28, 2020 |
| Priority date | Aug 30, 2017 |
| Publication date | Aug 6, 2020 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
An object of the present invention is to provide a cell transplant device having an ability to induce angiogenesis around the cell transplant device, and a method for manufacturing the same. According to the present invention, a cell transplant device including a cell structure (A) that includes a plurality of biocompatible polymer blocks and a plurality of cells of at least one type, and in which at least one of the biocompatible polymer blocks is disposed in gaps between the plurality of cells; and an immunoisolation membrane (B) that encloses the cell structure is provided.
Opening claim text (preview).
What is claimed is: 1 . A method for cell transplantation, which comprises transplanting, to a subject in need of angiogenesis, a cell transplant device including a cell structure (A) that has a plurality of biocompatible polymer blocks and a plurality of cells of at least one type, and in which at least one of the biocompatible polymer blocks is disposed in gaps between the plurality of cells; and an immunoisolation membrane (B) that encloses the cell structure. 2 . The method according to claim 1 , wherein a size of one of the biocompatible polymer blocks is 20 μm to 200 μm. 3 . The method according to claim 1 , wherein a biocompatible polymer in the biocompatible polymer block is cross-linked by heat, ultraviolet rays, or an enzyme. 4 . The method according to claim 1 , wherein the biocompatible polymer block is amorphous. 5 . The method according to claim 1 , wherein the cell structure includes 0.0000001 μg to 1 μg of biocompatible polymer blocks per cell. 6 . The method according to claim 1 , wherein the immunoisolation membrane is a porous membrane including a polymer. 7 . The method according to claim 6 , wherein a minimum pore diameter of the porous membrane is 0.02 μm to 1.5 μm. 8 . The method according to claim 6 , wherein a thickness of the porous membrane is 10 μm to 250 μm. 9 . The method according to claim 6 , wherein, within an inner side of the porous membrane, a layered compact portion in which a pore diameter is minimized is present, and a pore diameter continuously increases in a thickness direction from the compact portion toward at least one surface of the porous membrane. 10 . The method according to claim 9 , wherein a thickness of the compact portion is 0.5 μm to 30 μm. 11 . The method according to claim 6 , wherein a ratio of a maximum pore diameter to a minimum pore diameter of the porous membrane is 3.0 to 20.0. 12 . The method according to claim 6 , wherein the porous membrane contains at least one kind of polysulfone and polyvinylpyrrolidone.
Polyvinylpyrrolidone · CPC title
Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces · CPC title
Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials} · CPC title
Mixtures of macromolecular compounds · CPC title
Gelatin · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.